Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 14, 2023

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY(TM)

GlobeNewswire October 5, 2023

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

GlobeNewswire October 4, 2023

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

GlobeNewswire October 2, 2023

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire September 27, 2023

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY(TM) Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

GlobeNewswire September 25, 2023

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire September 22, 2023

Coherus Completes Surface Oncology Acquisition

GlobeNewswire September 8, 2023

Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

PR Newswire September 1, 2023

Coherus BioSciences to Participate at Upcoming September Investor Conferences

GlobeNewswire September 1, 2023

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote "FOR" the Proposed Merger with Coherus BioSciences

GlobeNewswire August 31, 2023

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire August 22, 2023

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

GlobeNewswire August 2, 2023

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

GlobeNewswire July 26, 2023

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire July 21, 2023

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

GlobeNewswire July 20, 2023

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY(TM)

GlobeNewswire July 13, 2023

Coherus Launches YUSIMRY(TM), a Biosimilar of Humira®, at $995 per Carton in U.S.

GlobeNewswire July 3, 2023

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire June 26, 2023

Coherus to Acquire Surface Oncology

GlobeNewswire June 16, 2023